Week

Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day

Retrieved on: 
Tuesday, March 29, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Infectious Diseases, Clinical Trials, Therapy, Cytokine, Plasma, Pharmacology, Malondialdehyde, Research, CEO, Psoriasis, PASI, Week, RASP, Nasdaq, Asthma, Development, Systemic disease, Patient, Pharmaceutical industry

Investigator global assessment scores decreased over the duration of treatment (p=0.01 vs. baseline at Week 12).

Key Points: 
  • Investigator global assessment scores decreased over the duration of treatment (p=0.01 vs. baseline at Week 12).
  • Plasma levels of the commonly described pro-inflammatory RASP malondialdehyde were reduced relative to baseline as soon as four weeks after initiation of treatment (p=0.02).
  • The R&D Day presentations are scheduled to begin at 10:00 a.m. (ET) today, March 29, 2022, in New York, NY.
  • Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue.

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

Retrieved on: 
Friday, March 25, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, People, Risk, Plaque, Medicine, Keck School of Medicine of USC, LinkedIn, Obesity, Therapy, Roivant Sciences, QD, AAD, Adult, Skin, PGA, Research, DLQI, Vitiligo, USC, Patient, Ageing, Hypertension, JD, Psoriasis, Quality of life, Irritation, Food, Atopic dermatitis, Aryl hydrocarbon receptor, PASI, Week, Safety, Diabetes, Twitter, Inflammatory bowel disease, Global Assessment of Functioning, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Academy, BSA, Dean (education), Dermatology Life Quality Index, Psoriasis Area and Severity Index, Efficiency, Depression, FDA, Acne, Pharmaceutical industry, MD, Dermatology, DERMAVANT’S PHASE 3 PROGRAM FOR TAPINAROF IN PSORIASIS, PSORIASIS, DERMAVANT

As a clinician, I am excited about the possibility of a potential new therapy in tapinarof for patients suffering from plaque psoriasis.

Key Points: 
  • As a clinician, I am excited about the possibility of a potential new therapy in tapinarof for patients suffering from plaque psoriasis.
  • Eligible patients who completed either PSOARING 1 or 2, which were 12-week pivotal studies of tapinarof in adults with plaque psoriasis, could enroll in PSOARING 3.
  • Patients who were randomized to tapinarof in PSOARING 1 or 2 and who also completed PSOARING 3 received tapinarof treatment for up to 52 weeks.
  • The company has reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis.

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults

Retrieved on: 
Thursday, March 24, 2022
Biotechnology, General Health, FDA, Health, Pharmaceutical, Disease, Risk, Respiratory syncytial virus, National, LinkedIn, Burden, Inc., Clinical trial, NYSE, High Risk, Breakthrough therapy, Vaccine, News, Pediatrics, Research, Woman, Pregnancy, Death, Food, Senior, PFE, Week, Food and Drug Administration, NIH, Safety, Twitter, U.S. Securities and Exchange Commission, Condition, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, DOI, RSV, Science, Centers for Disease Control and Prevention, Facebook, Center, Infection, YouTube, FDA, Protein, Antibody, Pharmaceutical industry, Medical device, Animal, Pfizer, RSVPREF, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.
  • The clinical and economic burden of RSV represents a critical need, and we look forward to our ongoing dialogue with the FDA to accelerate the development of our RSV vaccine candidate.
  • The vaccine candidate is composed of two preF proteins selected to optimize protection against RSV A and B.
  • Respiratory Syncytial Virus Infection (RSV) Older Adults are at High Risk for Severe RSV Infection Fact Sheet.

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

Retrieved on: 
Tuesday, March 22, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Glomerular filtration rate, Population, APOL1, Proteinuria, Medical Affairs Bureau, FSGS, Standard of care, Patient, Ageing, VRTX, UPCR, Week, Safety, Vertex, Vertex Pharmaceuticals, EGFR, FDA, Pharmaceutical industry

If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD.

Key Points: 
  • If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD.
  • APOL1-mediated kidney disease is a form of chronic kidney disease caused by mutations in the APOL1 gene.
  • Approximately 100,000 people in the U.S. and Europe have two APOL1 genetic mutations and proteinuric kidney disease.
  • Inherited APOL1 genetic mutations cause kidney disease through a toxic gain of function, which leads to podocyte injury.

Mathew S. Rosengart Receives Prestigious California Lawyer 'Attorney of the Year' Award

Retrieved on: 
Thursday, March 31, 2022
Rosengart, Variety, Public policy, LLP, Television, Daily Journal Corporation, Billboard, AM, NLJ, The National Law Journal, The American Lawyer, Lists of academic journals, The Hollywood Reporter, Sport, Carbon, Week, Industry, Law, Lawyer, Daily Journal, Film, Verizon Communications, Facebook

Rosengart has also been perennially recognized as one of the nation's leading litigators in media and entertainment by Variety and The Hollywood Reporter in their annual "Legal Impact" and Top 100 "Power Lawyer" Reports.

Key Points: 
  • Rosengart has also been perennially recognized as one of the nation's leading litigators in media and entertainment by Variety and The Hollywood Reporter in their annual "Legal Impact" and Top 100 "Power Lawyer" Reports.
  • The firm, often recognized for its focus on philanthropic giving, innovation, diversity, and pro bono, reported gross revenue of over $2 Billion for FY 2021.
  • The firm is consistently among the top firms on the Am Law 100, Am Law Global 100, NLJ 250, and Law360 (US) 400.
  • Greenberg Traurig is Mansfield Rule 4.0 Certified Plus by The Diversity Lab and net carbon neutral with respect to its office energy usage.

Greenberg Traurig's Mathew S. Rosengart Receives Prestigious California Lawyer Attorney of the Year Award

Retrieved on: 
Wednesday, March 30, 2022
Rosengart, Variety, Public policy, LLP, Television, Daily Journal Corporation, Billboard, AM, NLJ, The National Law Journal, The American Lawyer, Lists of academic journals, The Hollywood Reporter, Sport, Carbon, Week, Industry, Law, Lawyer, LOS, Daily Journal, Film, Verizon Communications, Facebook

LOS ANGELES, March 30, 2022 /PRNewswire-PRWeb/ -- Mathew S. Rosengart, a shareholder in global law firm Greenberg Traurig, LLP's Los Angeles office, was named a 2022 California Lawyer Attorney of the Year by the Los Angeles and San Francisco Daily Journal, which honors the state's top attorneys for their significant legal accomplishments and impact on public policy, law, and the profession over the past year.

Key Points: 
  • Rosengart has also been perennially recognized as one of the nation's leading litigators in media and entertainment by Variety and The Hollywood Reporter in their annual "Legal Impact" and Top 100 "Power Lawyer" Reports.
  • About Greenberg Traurig: Greenberg Traurig, LLP has more than 2400 attorneys in 42 locations in the United States, Europe, Latin America, Asia, and the Middle East.
  • The firm is consistently among the top firms on the Am Law 100, Am Law Global 100, NLJ 250, and Law360 (US) 400.
  • Greenberg Traurig is Mansfield Rule 4.0 Certified Plus by The Diversity Lab and net carbon neutral with respect to its office energy usage.

Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Friday, March 18, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Cream, Treatment, Abstract, Adult, Health care, Research, 2021 Essex County Council election, Knowledge, Ciclosporin, Solution, Disease, Security (finance), Inflammation, Marketing, American Academy of Dermatology, Shanda, Hidradenitis suppurativa, New Drug Application, Adolescence, U.S. Securities and Exchange Commission, Atopic dermatitis, JAK, Safety, Therapy, MAA, VALIANT, Clinical trial, AAD, Annual report, Azathioprine, Program, American Academy, Natural history, FDA, Company, Randomness, AD, Mental health, United, Week, Autoimmunity, COVID-19, Pharmaceutical industry, Cosmetics, Dermatology, Patient, Vitiligo, Incyte, Ruxolitinib Cream (Opzelura™), Incyte Dermatology, Incyte, RUXOLITINIB CREAM (OPZELURA™), INCYTE DERMATOLOGY, INCYTE

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting, held March 25-29, 2022, in Boston.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting, held March 25-29, 2022, in Boston.
  • Efficacy and Safety of Ruxolitinib Cream Monotherapy for the Treatment of Vitiligo: Results from Two 52-Week Phase 3 Studies (Session: S026 Late-Breaking Research: Clinical Trials.
  • ET; ePoster only)
    Full abstracts will be available on the AAD website on March 25, 2022.
  • Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.

OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine

Retrieved on: 
Wednesday, March 16, 2022
Â, Immunotherapy, OSE, Peptide, GLOBE, Patient, Immunity, Membrane protein, SARS, Fortification, Partnership, Immunodeficiency, Therapy, Boehringer Ingelheim, MERS, COVID-19, Large-cell lung carcinoma, Epitope, Capsid, Degenerative disease, Transplant, Week, IND, CD8, Clinical trial, Pancreatic cancer, ISIN, Cancer, Tissue, Severe acute respiratory syndrome coronavirus 2, Mnemos EP, Mab, Inflammation, Lung, PD-1, Nivolumab, Immune system, Longevity, Variants of SARS-CoV-2, IL-7, Coronavirus, Autoimmune disease, Ulcerative colitis, T cell, Vaccine, Pharmaceutical industry, Omicron, Delta

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.

Key Points: 
  • Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.
  • NANTES, France, March 16, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announces positive analysis of the long-term immune T cell responses of CoVepiT, its prophylactic vaccine candidate against COVID-19, with positive immunological results obtained at 6 months on T cell memory response in the vaccinated subjects.
  • This long term positive immune response is of strong interest (2) as more multispecific memory T cells are expected to be efficient for immunocompromised patients in case of any new emerging coronavirus or variants of concern.
  • In preclinical testing, CoVepiT demonstrated the ability to activate T cell defenses through CD8 T-cell multi-epitope responses for long-term T memory cell immunity.

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years

Retrieved on: 
Wednesday, March 16, 2022
Confusion, SVP, Swelling, Conference, Risk, MRI, Week, Nausea, MMSE, Medication, Headache, Nobel Prize, U.S. Securities and Exchange Commission, Drug development, Intellectual property, LinkedIn, Twitter, BIIB, Neurodegeneration, Magnetic resonance imaging, Private Securities Litigation Reform Act, Plasma, COVID-19, Spinal muscular atrophy, Cognition, Dizziness, Biomarker, Research, Population, ARIA, Patient, Multiple sclerosis, Neuroscience, Health, Nasdaq, Science, Lists of diseases, Brain, Allergy, Asilomar International Conference on Climate Intervention Technologies, Social media, Disease, YouTube, GLOBE, News, Failure, Climate, Safety, Amyloid, Incidence, Bleeding, Biotechnology, APOE, Pathology, Medical imaging, Pharmaceutical industry, Eisai, Biogen, Facebook

These data demonstrate that long-term treatment with ADUHELM continues to reduce the underlying pathologies of Alzheimers disease beyond two years."

Key Points: 
  • These data demonstrate that long-term treatment with ADUHELM continues to reduce the underlying pathologies of Alzheimers disease beyond two years."
  • In the placebo-controlled period of the Phase 3 trials, the incidence of ARIA-E in the 10 mg/kg group was 35.2%.
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.

Marie Claire Launches Best in Class Shopping Experience, Marie Claire Edit

Retrieved on: 
Wednesday, March 16, 2022
Guitar Player, Edit, Advertising, Acquisition, GLOBE, Future plc, Love, Digital camera, Knowledge, B2B, Nordstrom, Clothing, Future, Classic rock, Week, SEO, Sport, FourFourTwo, TechRadar, Beauty, TVTimes, Woman, Music Week, Photography, Nordstrom Rack, NYSE, Music, High fidelity, Toy, Interior design, Online shopping, Rack

Marie Claire Edit brings the ultimate shopping experience to readers, allowing them to shop thousands of stores via a single site.

Key Points: 
  • Marie Claire Edit brings the ultimate shopping experience to readers, allowing them to shop thousands of stores via a single site.
  • Marie Claire Edit creates a new way for customers to curate their wardrobe and engage with Marie Claires fashion and beauty content.
  • Designed and built in-house, leveraging Futures eCommerce expertise, Marie Claire Edit brings to life the influential women of Marie Claires industry-leading editorial team.
  • Marie Claire Edit is launching exclusively with Nordstrom for two months, with plans to expand to other fashion retailers shortly after.